DK17093D0 - Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder - Google Patents

Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder

Info

Publication number
DK17093D0
DK17093D0 DK93170A DK17093A DK17093D0 DK 17093 D0 DK17093 D0 DK 17093D0 DK 93170 A DK93170 A DK 93170A DK 17093 A DK17093 A DK 17093A DK 17093 D0 DK17093 D0 DK 17093D0
Authority
DK
Denmark
Prior art keywords
pct
vaccines
mammals
antigants
miles
Prior art date
Application number
DK93170A
Other languages
English (en)
Inventor
Sveinbjoern Gizurarson
Iver Heron
Original Assignee
Lyfjathroun H F
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyfjathroun H F, Statens Seruminstitut filed Critical Lyfjathroun H F
Priority to DK93170A priority Critical patent/DK17093D0/da
Publication of DK17093D0 publication Critical patent/DK17093D0/da
Priority to EP94907503A priority patent/EP0682528B1/en
Priority to US08/501,112 priority patent/US5942237A/en
Priority to JP6517549A priority patent/JPH09508614A/ja
Priority to PT94907503T priority patent/PT682528E/pt
Priority to CA002156084A priority patent/CA2156084A1/en
Priority to DK94907503T priority patent/DK0682528T3/da
Priority to ES94907503T priority patent/ES2150982T3/es
Priority to PCT/DK1994/000062 priority patent/WO1994017827A1/en
Priority to AT94907503T priority patent/ATE195077T1/de
Priority to DE69425427T priority patent/DE69425427T2/de
Priority to AU61065/94A priority patent/AU668290B2/en
Priority to OA60698A priority patent/OA10564A/en
Priority to NO19953182A priority patent/NO312057B1/no
Priority to GR20000402416T priority patent/GR3034727T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK93170A 1993-02-15 1993-02-15 Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder DK17093D0 (da)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DK93170A DK17093D0 (da) 1993-02-15 1993-02-15 Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
AU61065/94A AU668290B2 (en) 1993-02-15 1994-02-14 A pharmaceutical composition for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
DK94907503T DK0682528T3 (da) 1993-02-15 1994-02-14 Lægemiddelpræparat til topisk administration af antigener og/eller vacciner til pattedyr via en slimhindemembran
PCT/DK1994/000062 WO1994017827A1 (en) 1993-02-15 1994-02-14 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
JP6517549A JPH09508614A (ja) 1993-02-15 1994-02-14 哺乳動物に対する抗原類および／またはワクチン類の粘膜を介した局所投与のための医薬調製物
PT94907503T PT682528E (pt) 1993-02-15 1994-02-14 Uma preparacao farmaceutica para administracao topica de antigenios e/ou vacinas a mamiferos via uma membrana mucosa
CA002156084A CA2156084A1 (en) 1993-02-15 1994-02-14 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
EP94907503A EP0682528B1 (en) 1993-02-15 1994-02-14 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
ES94907503T ES2150982T3 (es) 1993-02-15 1994-02-14 Composicion farmaceutica para la administracion topica de antigenos y/o vacunas a mamiferos a traves de una membrana mucosa.
US08/501,112 US5942237A (en) 1993-02-15 1994-02-14 Pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
AT94907503T ATE195077T1 (de) 1993-02-15 1994-02-14 Ein pharmazeutisches präparat zur topischen verabreichung von antigenen und/oder vakzinen an die schleimhäute von säugern
DE69425427T DE69425427T2 (de) 1993-02-15 1994-02-14 Ein pharmazeutisches präparat zur topischen verabreichung von antigenen und/oder vakzinen an die schleimhäute von säugern
OA60698A OA10564A (en) 1993-02-15 1995-08-11 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane
NO19953182A NO312057B1 (no) 1993-02-15 1995-08-14 Farmasöytisk preparat for topisk administrering av antigener og/eller vaksiner til pattedyr via en slimhinnemembran, samtanvendelse av adjuvant
GR20000402416T GR3034727T3 (en) 1993-02-15 2000-10-30 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK93170A DK17093D0 (da) 1993-02-15 1993-02-15 Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder

Publications (1)

Publication Number Publication Date
DK17093D0 true DK17093D0 (da) 1993-02-15

Family

ID=8090567

Family Applications (2)

Application Number Title Priority Date Filing Date
DK93170A DK17093D0 (da) 1993-02-15 1993-02-15 Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
DK94907503T DK0682528T3 (da) 1993-02-15 1994-02-14 Lægemiddelpræparat til topisk administration af antigener og/eller vacciner til pattedyr via en slimhindemembran

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94907503T DK0682528T3 (da) 1993-02-15 1994-02-14 Lægemiddelpræparat til topisk administration af antigener og/eller vacciner til pattedyr via en slimhindemembran

Country Status (14)

Country Link
US (1) US5942237A (da)
EP (1) EP0682528B1 (da)
JP (1) JPH09508614A (da)
AT (1) ATE195077T1 (da)
AU (1) AU668290B2 (da)
CA (1) CA2156084A1 (da)
DE (1) DE69425427T2 (da)
DK (2) DK17093D0 (da)
ES (1) ES2150982T3 (da)
GR (1) GR3034727T3 (da)
NO (1) NO312057B1 (da)
OA (1) OA10564A (da)
PT (1) PT682528E (da)
WO (1) WO1994017827A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316745D0 (en) 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
CA2247388C (en) * 1996-01-25 2009-06-02 Sven-Erik Svehag Pharmaceutical composition comprising serum amyloid p component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
WO1999052549A1 (en) * 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
US7229621B2 (en) * 1998-10-20 2007-06-12 Torrey Pines Institute For Molecular Studies Method to enhance the immunogenicity of an antigen
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
EP1034792A1 (en) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
ATE376825T1 (de) * 1999-09-24 2007-11-15 Glaxosmithkline Biolog Sa Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
JP2006512401A (ja) * 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
WO2003016350A1 (en) * 2001-08-16 2003-02-27 Lyfjathroun H.F., Biopharmaceuticals A method of producing antibodies ex-vivo
KR100406503B1 (ko) * 2001-09-25 2003-11-19 한국과학기술연구원 폐렴구균성 표면 접착단백질의 가용화용 조성물, 가용화용액상제형, 및 가용화용 분말제형, 이들 각각의 제조방법및 백신
WO2003070273A1 (en) * 2002-02-25 2003-08-28 Lyfjathroun Hf A bioadhesive agent
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
JP5271475B2 (ja) 2002-11-26 2013-08-21 ザ ユニヴァーシティー オヴ シカゴ 微生物媒介上皮疾患の予防及び治療のための材料並びに方法
US20070184058A1 (en) * 2003-02-27 2007-08-09 Yaron Ilan Glucocerebroside treatment of pulmonary or respiratory diseases or disorders
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
AU2005329255B2 (en) 2004-04-15 2010-09-30 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
CN101123982B (zh) * 2005-01-28 2015-06-17 西北大学 脂质和一氧化二氮组合作为用于增强疫苗功效的佐剂
WO2006110699A1 (en) * 2005-04-11 2006-10-19 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
US20070036831A1 (en) * 2005-08-09 2007-02-15 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US20080038295A1 (en) * 2006-04-13 2008-02-14 Regents Of The University Of Michigan Compositions and methods for orthopox virus vaccination
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) * 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US20100047327A1 (en) * 2007-01-31 2010-02-25 Tetsuji Kuwahara Adjuvant for Transdermal or Transmucosal Administration and Pharmaceutical Preparation Containing the Same
EP2139993A2 (en) * 2007-04-27 2010-01-06 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
US9415006B2 (en) * 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
JP5623406B2 (ja) 2008-09-17 2014-11-12 キアズマ インコーポレイテッド 医薬組成物および関連する送達方法
ES2566646T3 (es) * 2009-06-16 2016-04-14 The Regents Of The University Of Michigan Vacunas en nanoemulsión
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
JP6114401B2 (ja) 2013-10-31 2017-04-12 久光製薬株式会社 アジュバント組成物、これを含むアジュバント製剤、及びキット
WO2015182735A1 (ja) * 2014-05-30 2015-12-03 キリン株式会社 乳酸菌免疫賦活作用増強組成物及び乳酸菌免疫賦活作用増強方法
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN111721937B (zh) * 2019-03-29 2023-04-07 北京九强生物技术股份有限公司 人附睾蛋白4免疫比浊试剂盒
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171125A (en) * 1966-06-08 1969-11-19 Glaxo Lab Ltd Improvements in or relating to Injectable Preparations
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
DE3446515A1 (de) * 1984-12-20 1986-06-26 Behringwerke Ag, 3550 Marburg Oeladjuvierte vaccine und verfahren zu ihrer herstellung
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
NL9000207A (da) * 1990-01-29 1991-08-16 Duphar Int Res
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines
EP0580778B1 (en) * 1991-04-19 1999-08-11 LDS Technologies, Inc. Convertible microemulsion formulations
IL102963A0 (en) * 1991-08-26 1993-01-31 Scripps Research Inst Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
CA2083553A1 (en) * 1991-11-25 1993-05-26 Kuniharu Seki Immunogen composition

Also Published As

Publication number Publication date
DE69425427D1 (de) 2000-09-07
OA10564A (en) 2002-06-20
US5942237A (en) 1999-08-24
DE69425427T2 (de) 2001-02-08
DK0682528T3 (da) 2000-12-27
GR3034727T3 (en) 2001-01-31
CA2156084A1 (en) 1994-08-18
PT682528E (pt) 2001-01-31
EP0682528B1 (en) 2000-08-02
EP0682528A1 (en) 1995-11-22
ES2150982T3 (es) 2000-12-16
NO953182L (no) 1995-10-12
NO953182D0 (no) 1995-08-14
NO312057B1 (no) 2002-03-11
ATE195077T1 (de) 2000-08-15
AU6106594A (en) 1994-08-29
JPH09508614A (ja) 1997-09-02
WO1994017827A1 (en) 1994-08-18
AU668290B2 (en) 1996-04-26

Similar Documents

Publication Publication Date Title
DK17093D0 (da) Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
KR950700758A (ko) 비-이온성 계면활성제 소포를 함유하는 백신(Vaccines containing non ionic surfactant vesicles)
ES8403024A1 (es) Un procedimiento para la fabricacion de un preparado farmaceutico para uso externo, a base de un compuesto no esteroi- dico.
DK0528859T3 (da) Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer
ES2150022T3 (es) Aerosol farmaceutico que contiene al menos un azucar.
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
TR200002930T2 (tr) Kolaylaştırıcı kompozisyonlar
NO982497L (no) Vaksine-sammensetninger for inntak gjennom nesen
YU28392A (sh) Vakcina koja sadrži glikoprotein d i 3deacilovani monofosforil lipid a
IT8619675A0 (it) Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale.
NO943341L (no) Sammensetninger for orale preparater
AU2001295673A1 (en) Vaccine composition
IT8821324A0 (it) Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
PT692974E (pt) Vacinas clostridiais com multiplos componentes usando adjuvantes de saponina
FR2682114B1 (fr) Vaccin de sous-unite contre les infections a neisseria meningitidis et sous-unites correspondantes a l'etat purifie.
Sanchez et al. Immunological response to Vibrio cholerae O1 infection and an oral cholera vaccine among Peruvians
BR0007513A (pt) Fosfatidilinositóis sulfatados, sua preparação euso
MX9302272A (es) Retinoides solubles en agua.
IT8609514A0 (it) Utilizzazione di ottilonio bromuro (dci) per applicazione topica nel tratto gastro-intestinale e relativa formulazione farmaceutica appropriata per tale uso.
Braun et al. Multicomponent strategies to prevent SARS-CoV-2 Transmission—nine overnight youth summer camps, US June–August 2021
NO943251L (no) Oral vaksine
IT8819669A0 (it) 2_0_acetil_1,3bis(difosforil_colina)_glicerolo procedimento per la sua preparazione e suo uso terapeutico.
TH12267A (th) สารผสมชนิดเจลซึ่งควบคุมน้ำมันได้ดีขึ้น

Legal Events

Date Code Title Description
A0 Application filed
AHS Application shelved for other reasons than non-payment